Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

Cancer Research
Bohua LiYajun Guo

Abstract

To develop more effective anti-CD20 reagents for B-cell lymphoma, we designed and constructed a bispecific tetravalent anti-CD20 antibody, 11B8/2F2(ScFvHL)(4)-Fc, derived from two fully human monoclonal antibodies (mAb), 2F2 and 11B8. 2F2 is a type I CD20 mAb, which is potent in complement-dependent cytotoxicity (CDC) assays but poor at inducing apoptosis, whereas 11B8 is a type II CD20 mAb, which is effective in induction of apoptosis but ineffective in CDC. Our results showed that 11B8/2F2(ScFvHL)(4)-Fc possessed apoptosis-inducing activity markedly superior to that of 2F2, and even 11B8, 11B8 plus 2F2, and 2F2(ScFvHL)(4)-Fc, a 2F2-derived monospecific tetravalent antibody developed previously. Interestingly, 11B8/2F2(ScFvHL)(4)-Fc displayed a similar ability to mediate CDC as 2F2(ScFvHL)(4)-Fc, although two of its four antigen-binding arms originated from 11B8. To explore why 11B8/2F2(ScFvHL)(4)-Fc was so potent in both CDC and apoptotic activity, a bispecific divalent antibody composed of 2F2 and 11B8, denoted as 11B8/2F2-ScFvFc, was constructed and characterized. Our results partially explained the reason for the potent CDC and apoptosis-inducing activity of 11B8/2F2(ScFvHL)(4)-Fc. Further in vivo therapy studies showed th...Continue Reading

References

Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A GhetieE S Vitetta
Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 18, 1998·Current Opinion in Oncology·G A Leget, M S Czuczman
Feb 15, 2002·British Journal of Haematology·L E van der KolkM H van Oers
Jun 24, 2003·Drug Discovery Today·Martin J Glennie, Jan G J van de Winkel
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruiqi MengVictor Ghetie
Jun 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jessica L TeelingJan G J van de Winkel
Jul 28, 2006·CA: a Cancer Journal for Clinicians·Robert M Sharkey, David M Goldenberg
Sep 5, 2007·Molecular Immunology·Martin J GlennieRonald P Taylor

❮ Previous
Next ❯

Citations

Sep 29, 2019·Current Hematologic Malignancy Reports·Pallawi TorkaFrancisco J Hernandez-Ilizaliturri
Oct 20, 2017·Frontiers in Immunology·Michael J E MarshallMark S Cragg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.